A material transfer agreement is a contract that governs the transfer of tangible research materials from one organization to another, spelling out what the recipient can and cannot do with the materials, who owns any resulting inventions, and how liability is handled if something goes wrong.1AUTM. Material Transfer Agreements These agreements appear constantly in academic, government, and industry research, and the paperwork ranges from a quick signature on a standardized form to months of back-and-forth over intellectual property.
What Materials Are Covered
MTAs apply to physical research materials sent between institutions for scientific work. The most common transfers involve biological materials: cell lines, plasmids, proteins, transgenic animals, bacteria, and pharmaceuticals or other chemical compounds.1AUTM. Material Transfer Agreements Software and certain data can fall under an MTA when bundled with physical materials or when they carry proprietary restrictions.
The scope runs broader than many researchers expect. Human-derived materials, including tissue samples, blood, DNA, and even waste products like hair or urine, frequently require MTAs with additional regulatory layers. Plant varieties, novel chemical compounds under development, and proprietary reagents all qualify. If it is a tangible item with research value and someone else created it, there is a good chance an MTA stands between you and it.
The Core Provisions
Terms vary, but a handful of provisions appear in nearly every MTA. These are the places to focus before signing.
Permitted Use and Redistribution
The provider typically restricts the recipient to non-commercial research purposes and prohibits transferring the materials to anyone else. Under widely accepted standards, the recipient should not sell, lease, or license the materials to third parties, and commercially oriented work such as fee-for-service projects may be explicitly off-limits.2AUTM. MTA Guiding Principles Even inside the recipient’s own institution, use is generally limited to researchers working under the direction of the named principal investigator.
Intellectual Property
IP is where most negotiations get stuck. The baseline is that the provider keeps ownership of the original materials, including any material the recipient incorporates into new substances. Beyond that, the provider should have no rights to inventions the recipient makes while using the material, and should not restrict what the recipient does with inventions created solely by the recipient’s scientists.2AUTM. MTA Guiding Principles In practice, some providers push for “reach-through” rights claiming a share of downstream discoveries or revenues. That is one of the most contentious terms in MTA negotiations and a frequent source of delay.
Publication Rights
Academic researchers care deeply about the right to publish. The recommended standard is that providers should not require pre-review of publications or demand a copy of manuscripts, since published work is public anyway. A provider may reasonably ask the recipient to acknowledge the source of the materials.2AUTM. MTA Guiding Principles Some providers nonetheless insist on a pre-publication review period, which can delay time-sensitive findings.
Confidentiality
Under recommended standards, there should be no blanket requirement to treat research results or the materials themselves as confidential. Recipients should remain free to disclose their own results. If the provider shares unpublished proprietary information alongside the materials, however, it can reasonably ask that information to be kept confidential under standard terms, including that the information be provided in writing and clearly marked.2AUTM. MTA Guiding Principles
Liability and Warranties
Providers almost always disclaim any guarantee that the materials will work for a particular purpose or are safe in any specific application. Each party should accept liability for its own actions: the recipient takes responsibility for how it uses the materials, while the provider bears responsibility for losses caused by its own gross negligence or misconduct. The recommended position is that providers should not require indemnification from the recipient.2AUTM. MTA Guiding Principles
Termination and Governing Law
MTAs specify when the agreement ends, such as completion of the project or a breach of terms, and most require the recipient to return or destroy unused materials on termination. A governing law clause designates which jurisdiction’s law controls disputes. These clauses rarely cause negotiation problems, but they matter if a conflict reaches a courtroom.
Standardized Frameworks That Speed Things Up
Negotiating a custom MTA for every transfer would grind research to a halt. Two standardized frameworks exist to streamline transfers between nonprofit institutions, and knowing whether one applies to your transfer can save weeks.
Uniform Biological Material Transfer Agreement
The Uniform Biological Material Transfer Agreement (UBMTA) was developed by the NIH, working with representatives from academia and industry, to simplify exchange of proprietary biological materials among nonprofit institutions.3National Institutes of Health. NIH Guide – Uniform Biological Material Transfer Agreement Institutions sign the UBMTA Master Agreement once, and then individual transfers between any two signatory institutions happen through a short implementing letter describing the specific materials. The implementing letter references the pre-agreed terms, so no separate contract has to be negotiated.
NIH Simple Letter Agreement
The NIH Simple Letter Agreement (SLA) is a lighter-touch option. It is the preferred model for the NIH intramural program when transferring non-human, non-animal, non-hazardous research materials to nonprofit organizations for research and teaching.4National Institutes of Health. NIH SLA Policy NIH policy states that most transfers to nonprofit entities should use terms no more restrictive than the UBMTA or the SLA, which sets a useful ceiling for what providers can reasonably demand.
Who Signs and How Long It Takes
Individual researchers cannot sign MTAs on their own behalf. The agreement must be signed by someone authorized to approve intellectual property agreements for the entire institution, because the signatory binds the institution to every obligation in the contract. At most organizations the technology transfer office, sponsored research office, or legal office handles review and execution. At smaller organizations without those offices, a dean or director may hold signing authority.
Timelines vary with complexity. When both institutions have signed the UBMTA, an implementing letter can be completed in days. Custom agreements take longer, typically a few weeks to several months, and transfers involving commercial organizations or foreign entities tend to run longer because their preferred terms often conflict with the recipient institution’s policies or federal funding requirements.
Federal Funding and the Bayh-Dole Act
When research materials were developed with federal funds, the Bayh-Dole Act adds obligations the parties cannot negotiate away. Under 35 U.S.C. ยง 202, nonprofit organizations and small businesses that receive federal funding generally retain the right to title any inventions made under the funding agreement, but they must disclose each invention to the federal agency within a reasonable time after it becomes known to their patent administration personnel.5GovInfo. United States Code Title 35 Part II Chapter 18 – Patent Rights in Inventions Made with Federal Assistance
NIH policy requires that unique research resources developed with NIH funds be made readily available to qualified researchers in the scientific community once the associated findings are accepted for publication. Recipients of NIH awards must also provide a copy of documents or a sample of materials on request of the awarding NIH office, and the terms of any MTA covering those materials must reflect Bayh-Dole’s objectives of promoting free competition and enterprise without unduly burdening future research.6National Institutes of Health. NIH Grants Policy Statement – Sharing Research Resources An NIH-funded provider cannot use an MTA to lock down materials with overly restrictive terms that would block other scientists from building on the work.
Human Materials and Export Controls
Two categories of transfer trigger regimes that sit on top of the MTA itself, and overlooking either can create serious liability.
For human biological samples, NIH generally requires that materials be transferred only after Institutional Review Board (IRB) or Office of Human Subjects Research review and approval, and the provider must confirm that the original consent documents are not inconsistent with sharing the materials with the recipient.7National Institutes of Health. NIH Human Materials Transfer Policy Even derivatives of originally human materials may require IRB review, particularly when the materials are identified or coded. When protected health information accompanies the materials, HIPAA requires either authorization from the individuals involved, a waiver from an IRB or privacy board, or de-identification before transfer.
Transfers to foreign institutions or foreign nationals can trigger federal export control laws even when the transfer occurs within the United States. The International Traffic in Arms Regulations cover military technology and related technical data; the Export Administration Regulations cover dual-use items with both commercial and military applications. Many fundamental research materials are exempt under a “fundamental research exclusion,” but the exemption can be lost when an MTA includes publication restrictions or access limitations on foreign nationals. Penalties for violations are severe, including potential criminal prosecution and debarment from government contracts, so international MTAs are typically routed through an export control office for screening before execution.
What Happens If You Breach
An MTA is an enforceable contract, so breaching its terms exposes the violating party to the same remedies as any other contract breach. In most cases that means civil liability, not criminal consequences. The injured party can seek compensatory damages for direct losses, consequential damages for foreseeable indirect harm such as lost commercial opportunities, or specific performance compelling the breaching party to do what the contract required. Courts may also issue injunctions ordering the violator to stop specific activities, such as continuing to use materials after termination.
The practical consequences often matter more than the legal ones. Research communities are smaller than they appear, and a reputation for ignoring MTA terms makes other institutions reluctant to share materials. For institutions receiving federal funding, a breach that violates NIH sharing policies could also jeopardize future grant awards.